197 related articles for article (PubMed ID: 30898839)
1. Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors.
Wojcik JB; Marchione DM; Sidoli S; Djedid A; Lisby A; Majewski J; Garcia BA
Cancer Res; 2019 Jul; 79(13):3205-3219. PubMed ID: 30898839
[TBL] [Abstract][Full Text] [Related]
2. Poly Combs the Immune System: PRC2 Loss in Malignant Peripheral Nerve Sheath Tumors Can Dampen Immune Responses.
Natarajan SK; Venneti S
Cancer Res; 2019 Jul; 79(13):3172-3173. PubMed ID: 31262833
[TBL] [Abstract][Full Text] [Related]
3. Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss.
Marchione DM; Lisby A; Viaene AN; Santi M; Nasrallah M; Wang LP; Williams EA; Larque AB; Chebib I; Garcia BA; Wojcik JB
Mod Pathol; 2019 Oct; 32(10):1434-1446. PubMed ID: 31175328
[TBL] [Abstract][Full Text] [Related]
4. Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors.
Thangaiah JJ; Westling BE; Roden AC; Giannini C; Tetzlaff M; Cho WC; Folpe AL
Ann Diagn Pathol; 2022 Aug; 59():151967. PubMed ID: 35567887
[TBL] [Abstract][Full Text] [Related]
5. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
Zhang X; Murray B; Mo G; Shern JF
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
[TBL] [Abstract][Full Text] [Related]
6. PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.
Patel AJ; Warda S; Maag JLV; Misra R; Miranda-Román MA; Pachai MR; Lee CJ; Li D; Wang N; Bayshtok G; Fishinevich E; Meng Y; Wong EWP; Yan J; Giff E; Pappalardi MB; McCabe MT; Fletcher JA; Rudin CM; Chandarlapaty S; Scandura JM; Koche RP; Glass JL; Antonescu CR; Zheng D; Chen Y; Chi P
Cancer Discov; 2022 Sep; 12(9):2120-2139. PubMed ID: 35789380
[TBL] [Abstract][Full Text] [Related]
7. Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
Korfhage J; Lombard DB
Mol Cancer Res; 2019 Jul; 17(7):1417-1428. PubMed ID: 31023785
[TBL] [Abstract][Full Text] [Related]
8. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
Kochat V; Raman AT; Landers SM; Tang M; Schulz J; Terranova C; Landry JP; Bhalla AD; Beird HC; Wu CC; Jiang Y; Mao X; Lazcano R; Gite S; Ingram DR; Yi M; Zhang J; Keung EZ; Scally CP; Roland CL; Hunt KK; Feig BW; Futreal PA; Hwu P; Wang WL; Lazar AJ; Slopis JM; Wilson-Robles H; Wiener DJ; McCutcheon IE; Wustefeld-Janssens B; Rai K; Torres KE
Acta Neuropathol; 2021 Sep; 142(3):565-590. PubMed ID: 34283254
[TBL] [Abstract][Full Text] [Related]
9. Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
Röhrich M; Koelsche C; Schrimpf D; Capper D; Sahm F; Kratz A; Reuss J; Hovestadt V; Jones DT; Bewerunge-Hudler M; Becker A; Weis J; Mawrin C; Mittelbronn M; Perry A; Mautner VF; Mechtersheimer G; Hartmann C; Okuducu AF; Arp M; Seiz-Rosenhagen M; Hänggi D; Heim S; Paulus W; Schittenhelm J; Ahmadi R; Herold-Mende C; Unterberg A; Pfister SM; von Deimling A; Reuss DE
Acta Neuropathol; 2016 Jun; 131(6):877-87. PubMed ID: 26857854
[TBL] [Abstract][Full Text] [Related]
10. H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.
Lyskjaer I; Lindsay D; Tirabosco R; Steele CD; Lombard P; Strobl AC; Rocha AM; Davies C; Ye H; Bekers E; Ingruber J; Lechner M; Amary F; Pillay N; Flanagan AM
J Pathol; 2020 Oct; 252(2):151-164. PubMed ID: 32666581
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and prognostic significance of H3K27 methylation status in malignant peripheral nerve sheath tumor: correlation with skeletal muscle differentiation.
Ito Y; Kohashi K; Endo M; Yoshimoto M; Ishihara S; Toda Y; Susuki Y; Kawaguchi K; Furukawa H; Tateishi Y; Yamada Y; Kinoshita I; Mori T; Yamamoto H; Nakashima Y; Oda Y
Virchows Arch; 2021 Dec; 479(6):1233-1244. PubMed ID: 34432163
[TBL] [Abstract][Full Text] [Related]
12. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
[TBL] [Abstract][Full Text] [Related]
13.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
14. [Targeted therapy for malignant peripheral nerve sheath tumor: translational research and clinical application].
Liao ZC; Zhang C; Liu XY; Ren ZW; Xu J; Zhang CZ; Yang Y; Zhu Z; Yang JL
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):648-653. PubMed ID: 31550853
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.
Otsuka H; Kohashi K; Yoshimoto M; Ishihara S; Toda Y; Yamada Y; Yamamoto H; Nakashima Y; Oda Y
Pathol Res Pract; 2018 Mar; 214(3):417-425. PubMed ID: 29482987
[TBL] [Abstract][Full Text] [Related]
16. CDX2 expression in malignant peripheral nerve sheath tumour: a potential diagnostic pitfall associated with PRC2 inactivation.
Odeyemi OO; Ozawa MG; Charville GW
Histopathology; 2022 May; 80(6):995-1000. PubMed ID: 35122289
[TBL] [Abstract][Full Text] [Related]
17. Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor.
Zhang X; Lou HE; Gopalan V; Liu Z; Jafarah HM; Lei H; Jones P; Sayers CM; Yohe ME; Chittiboina P; Widemann BC; Thiele CJ; Kelly MC; Hannenhalli S; Shern JF
Cell Rep; 2022 Sep; 40(12):111363. PubMed ID: 36130486
[TBL] [Abstract][Full Text] [Related]
18. Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.
Cortes-Ciriano I; Steele CD; Piculell K; Al-Ibraheemi A; Eulo V; Bui MM; Chatzipli A; Dickson BC; Borcherding DC; Feber A; Galor A; Hart J; Jones KB; Jordan JT; Kim RH; Lindsay D; Miller C; Nishida Y; Proszek PZ; Serrano J; Sundby RT; Szymanski JJ; Ullrich NJ; Viskochil D; Wang X; Snuderl M; Park PJ; Flanagan AM; Hirbe AC; Pillay N; Miller DT;
Cancer Discov; 2023 Mar; 13(3):654-671. PubMed ID: 36598417
[TBL] [Abstract][Full Text] [Related]
19. Epigenomic Regulation of Schwann Cell Reprogramming in Peripheral Nerve Injury.
Ma KH; Hung HA; Svaren J
J Neurosci; 2016 Aug; 36(35):9135-47. PubMed ID: 27581455
[TBL] [Abstract][Full Text] [Related]
20. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.
Schaefer IM; Fletcher CD; Hornick JL
Mod Pathol; 2016 Jan; 29(1):4-13. PubMed ID: 26585554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
